Janus Capital Management LLC cut its stake in shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) by 0.2% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 1,424,583 shares of the biopharmaceutical company’s stock after selling 2,353 shares during the period. Janus Capital Management LLC owned approximately 3.88% of Aratana Therapeutics worth $7,550,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of PETX. Woodstock Corp boosted its position in Aratana Therapeutics by 120.0% in the first quarter. Woodstock Corp now owns 71,906 shares of the biopharmaceutical company’s stock valued at $381,000 after buying an additional 39,226 shares during the period. A.R.T. Advisors LLC boosted its position in Aratana Therapeutics by 19.3% in the fourth quarter. A.R.T. Advisors LLC now owns 17,900 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 2,900 shares during the period. Capital Fund Management S.A. purchased a new position in Aratana Therapeutics during the first quarter valued at approximately $282,000. Wells Fargo & Company MN boosted its position in Aratana Therapeutics by 281.4% in the first quarter. Wells Fargo & Company MN now owns 276,152 shares of the biopharmaceutical company’s stock valued at $1,464,000 after buying an additional 203,738 shares during the period. Finally, Cadence Capital Management LLC boosted its position in Aratana Therapeutics by 21.7% in the first quarter. Cadence Capital Management LLC now owns 131,926 shares of the biopharmaceutical company’s stock valued at $699,000 after buying an additional 23,506 shares during the period. 67.85% of the stock is owned by hedge funds and other institutional investors.
Aratana Therapeutics, Inc. (PETX) traded down 3.04% during midday trading on Tuesday, reaching $6.07. The company had a trading volume of 384,107 shares. The stock’s market cap is $230.40 million. Aratana Therapeutics, Inc. has a 12 month low of $4.97 and a 12 month high of $10.73. The firm has a 50-day moving average of $7.07 and a 200-day moving average of $6.46.
Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. The business had revenue of $5.16 million during the quarter, compared to analysts’ expectations of $4.50 million. Aratana Therapeutics had a negative return on equity of 52.00% and a negative net margin of 642.93%. The firm’s revenue for the quarter was down 86.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.61 earnings per share. On average, equities analysts expect that Aratana Therapeutics, Inc. will post ($1.04) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first published by Markets Daily and is owned by of Markets Daily. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.themarketsdaily.com/2017/08/08/janus-capital-management-llc-has-7-55-million-stake-in-aratana-therapeutics-inc-petx-updated-updated-updated.html.
Several equities analysts have commented on PETX shares. ValuEngine cut Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 31st. Stifel Nicolaus dropped their target price on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, May 10th. Jefferies Group LLC reissued a “buy” rating and issued a $8.00 target price on shares of Aratana Therapeutics in a report on Friday, May 5th. BidaskClub cut Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 target price for the company in a report on Tuesday, July 4th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $10.00.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.